MEDICAL ADVOCATES
NEW AND NEWSWORTHY
Drug/Vaccine Archives

Back to New and Noteworthy

Files identified with this icon are in Portable Document Format (PDF) and
require the Adobe Acrobat Reader

Date

Drug

Citation

July 22 2008	Peginterferon (HCV Indications)	Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

July 21 2008	Atazanavir Lopinavir	No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

July 19/20 2008	Maraviroc	Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions. [

July 18 2008	Lopinavir	Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors - Study PACTG P1038.

July 17 2008	Tipranavir	Tipranavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

July 16 2008	Nevirapine	Risk for immune-mediated liver reactions by nevirapine revisited.

July 15 2008	Darunavir	Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

July 14 2008	Tipranavir	New resistance score for tipranavir .

July 12/13 2008	Abacavir Pegylated Interferon	Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

July 11 2008\|	Interferon	Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.

July 10 2008\|\|	Darunavir	Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects: Phase I Randomized, Open-Label, Two-Way Crossover Study..

July 09 2008	Fosamprenavir	Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.

July 08 2008	Didanosine	Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response.

July 07 2008	Nevirapine	Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

July 05/06 2008	Pegylated IFN-alpha2b	Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.

July 04 2008	Anidulafungin (Candidiasis Indication)	Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis.

July 03 2008	Pegylated Liposomal Doxorubicin (Kaposi's Sarcoma Indications)	Long-Term Prognosis of HIV-Infected Patients with Kaposi Sarcoma Treated with Pegylated Liposomal Doxorubicin.

July 02 2008	Lamivudine Stavudine	Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.

July 01 2008	Tenofovir	Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

June 30 2008	Tipranavir	Tipranavir: A Review of its Use in the Management of HIV Infection.

June 28/29 2008	Ritonavir	Induction Effects of Ritonavir: Implications for Drug Interactions,

June 26 2008	Enfuvirtide	A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).

June 26 2008	Atazanavir	Effects of Minocycline and Valproic acid Coadministration on Atazanavir Plasma Concentrations in HIV-infected Adults Receiving Atazanavir/Ritonavir.

June 25 2008	Peginterferon and HIV/HCV Coinfection	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

June 24 2008	Atazanavir	Ritonavir-Boosted Atazanavir, Methadone, and Ventricular Tachycardia: 2 Case Reports.

June 23 2008	Etravirine \|	CONFERENCE PDF POSTER Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)

June 21/22 2008	Darunavir	CONFERENCE PDF POSTER Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2

June 20 2008	Lopinavir	Safety of Long-term Lopinavir Plasma-levels in Patients with Liver Disease. L

June 19 2008	Enfuvirtide	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

June 18 2008	Atazanavir	Atazanavir in Patients with Persistent Viral Replication Despite HAART: Results from the French Prospective NADIS Cohort.

June 17 2008	Abacavir/Lamivudine	Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Na�ve Patients: A 48-Week Pilot Study.

June 16 2008	Stavudine	Randomization to once-daily Stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.

June 14/15 2008	Darunavir	Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
June 04 2008	Enfuvirtide	An Open-Label Safety Study of Enfuvirtide Injection with a Needle-Free Injection Device or Needle/Syringe: The Biojector 2000 Open-Label Safety Study (BOSS).

June 03 2008	Peginterferon alfa-2a Peginterferon alfa-2b	Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin.

June 02, 2008	Atazanavir	Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring.

Back to New and Noteworthy

Drug Update Archives